Walk into any pharmacy and ask for something “for your liver”, and you will almost certainly be handed milk thistle. It has been used for the liver for the better part of two thousand years, it is cheap, it is safe, and its name is practically a synonym for liver support. TUDCA — tauroursodeoxycholic acid — is the opposite: barely known outside enthusiast circles, harder to pronounce, and quietly becoming the choice of people who actually read the studies. They are both sold “for the liver.” But they are not remotely the same thing, and once you understand how each works, the reputations start to look upside down.

Two completely different tools

The most important thing to grasp is that these two do not compete on the same mechanism — they barely operate in the same part of the cell. Milk thistle’s active fraction is silymarin, a complex of plant flavonolignans (chiefly silybin). Its recognised actions are those of a good antioxidant: it neutralises free radicals, damps inflammation, and helps stabilise the outer membrane of liver cells against toxins.¹ In other words, it works largely from the outside, as a defensive shield.

TUDCA is not a plant compound at all — it is a bile acid, a molecule your own body already makes, just the gentlest, most water-soluble member of the family. And it works from inside the cell, on the machinery itself.

Same goal, opposite strategy. Milk thistle’s silymarin is essentially a plant antioxidant: it works largely from outside the liver cell, neutralising free radicals and steadying the cell membrane like a shield. TUDCA is a bile acid that works from inside: it eases the cell’s internal stress systems, helps its proteins fold, and keeps bile flowing gently. One defends the cell; the other tunes its machinery.

That inside-versus-outside distinction is the whole story, so it is worth being concrete about what “from the inside” actually means.

How TUDCA works: three jobs at once

TUDCA is unusual in doing several quite different things simultaneously. First, because it is such a mild, water-soluble bile acid, adding it shifts the whole bile-acid pool toward the gentle end — diluting the harsher, more detergent-like bile acids that stress liver cells when they back up. This is the same principle behind its parent drug, more on which shortly.² Second, it acts as a chemical chaperone: it calms stress in the endoplasmic reticulum (the cell’s protein-folding factory) and helps misfolded proteins fold correctly instead of piling up into damage — a mechanism demonstrated strikingly in a landmark study where chemical chaperones restored glucose control in diabetic mice.³ Third, it stabilises mitochondria and blunts the signal for premature cell death (apoptosis), a mechanism worked out in detail across a series of studies.^4,5

What “from the inside” means. TUDCA is unusual in acting three ways at once: it shifts the mix of bile acids toward the gentle, water-soluble end (easing the cholestatic stress that damages liver cells), it behaves as a chemical chaperone that calms endoplasmic-reticulum stress and helps proteins fold correctly, and it stabilises mitochondria to blunt premature cell death. This is machinery-level support, not just antioxidant defence.

None of these is an antioxidant action in the milk-thistle sense. TUDCA is not mopping up damage after the fact — it is tuning the systems that decide whether a stressed liver cell copes or fails.

Milk thistle: the famous one, examined honestly

Milk thistle’s antioxidant rationale is real and reasonable, and its safety record over centuries is excellent — two genuine points in its favour.¹ It has two well-known practical drawbacks, though. The first is bioavailability: silymarin is poorly water-soluble and poorly absorbed from the gut, so a good deal of what you swallow never reaches the bloodstream, which is why formulations go to such lengths to improve uptake. The second is more awkward, and it is the part the marketing tends to skip.

What the clinical trials actually found

Here is the uncomfortable bit for the most famous liver supplement in the world: when milk thistle has been put to rigorous test for hard liver outcomes, it has mostly underwhelmed. A Cochrane systematic review pooled 13 randomised trials in more than 900 patients with alcohol-related or viral (hepatitis B/C) liver disease and could find no significant effect on mortality, on complications of liver disease, or on liver histology — and noted that most of the trials were low quality to begin with.⁶ A rigorous, NIH-funded randomised trial then tested a higher-than-usual dose of silymarin in people with hepatitis C and found it no better than placebo at reducing liver enzymes.⁷ This does not make milk thistle a scam — it makes it a safe antioxidant whose blockbuster reputation as a daily “liver detox” has simply run far ahead of what the controlled evidence supports.

To be fair — because fairness is the point of this Journal — milk thistle does have one genuinely proven, dramatic use. An intravenous, standardised form of its active (silibinin, sold as Legalon SIL) is a recognised hospital antidote for death-cap mushroom poisoning, where it blocks the amatoxin from being taken up into liver cells and has helped patients avoid liver failure.⁸ That is a real, life-saving application — but note what it is: a specific, high-dose, intravenous emergency treatment, not evidence that a capsule a day “detoxifies” a healthy liver.

TUDCA: the newcomer with a pedigree

TUDCA looks the other way round: less famous, but with a mechanistic and clinical pedigree that milk thistle cannot match. The strongest card is family. TUDCA’s near-twin, UDCA (ursodeoxycholic acid, sold as ursodiol), is not a supplement at all — it is an approved prescription medicine, the standard of care for cholestatic liver conditions such as primary biliary cholangitis, precisely because of the gentle-bile-acid mechanism above.² TUDCA is UDCA with a taurine group attached, which makes it even more water-soluble and, in principle, better absorbed.

On its own account, TUDCA has something milk thistle largely lacks: human data on the liver’s actual biology. In a controlled study, four weeks of TUDCA measurably improved insulin sensitivity in the liver and muscle of people with obesity — a real, mechanism-consistent effect in humans, not a mouse or a test tube.⁹ Its chaperone and anti-apoptotic actions have been mapped across an unusually detailed body of mechanistic work,^3,4 and reviews now catalogue a growing list of uses for the urso-/tauro-bile-acid family reaching well beyond the liver.¹⁰ The evidence base is younger and smaller than milk thistle’s — but it is pointed at the machinery, and it is moving in one direction.

How they stack up

Milk thistleTUDCA

Centuries of traditional use✓~

Antioxidant / free-radical defence✓~

A proven emergency use✓—

Acts on the cell’s internal machinery—✓

Human data on the liver’s own biology~✓

An approved medicine in its family—✓

An honest scorecard. This is not a knockout — each wins genuine points. Milk thistle has the history, the antioxidant credentials and one rock-solid clinical use; TUDCA has the deeper mechanism, the human liver-biology data and a prescription-drug relative. They are good at different things — which is the whole point of choosing deliberately rather than by name recognition.

Read that scorecard honestly and neither “wins.” If you want a cheap, time-tested, low-risk antioxidant and you are comfortable that the hard-endpoint trials are thin, milk thistle is a perfectly reasonable thing to take. If you want the compound that works on the liver cell’s internal stress systems, that has human data on liver biology, and whose chemical family is established medicine, TUDCA is the more interesting daily choice.

So which should you take?

Our honest read: for everyday, mechanism-first liver support, TUDCA is the stronger pick, and it is the one we built around — it is doing something more targeted than antioxidant defence, and its pedigree is hard to argue with. Milk thistle is not a mistake; it is a safe, familiar, antioxidant option whose real-world evidence is simply softer than its fame implies. The two are also not mutually exclusive — because they act by entirely different routes, some people take both. One last, important point: neither is a treatment for liver disease. If you have a diagnosed liver condition or take medication, this is a conversation for your doctor, not a supplement label. This is general information, not medical advice.

Where you’ll find it

SAP TUDCA delivers 500 mg of tauroursodeoxycholic acid per serving — the gentle bile acid your liver already recognises, at a dose in line with the research. If you want the full mechanism — how a bile acid becomes a chemical chaperone, and why the taurine version matters — our deep-dive on TUDCA takes it further.

References

Peer-reviewed sources for the comparisons and findings above, offered for further reading. Nothing here is medical advice or a claim to treat, cure or prevent any condition.

Abenavoli L, Izzo AA, Mili&cacute; N, Cicala C, Santini A, Capasso R. Milk thistle (Silybum marianum): a concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases. Phytother Res. 2018;32(11):2202–2213.
Beuers U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol. 2006;3(6):318–328.
Özcan U, Yilmaz E, Özcan L, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science. 2006;313(5790):1137–1140.
Rodrigues CMP, Fan G, Ma X, Kren BT, Steer CJ. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest. 1998;101(12):2790–2799.
Amaral JD, Viana RJ, Ramalho RM, Steer CJ, Rodrigues CM. Bile acids: regulation of apoptosis by ursodeoxycholic acid. J Lipid Res. 2009;50(9):1721–1734.
Rambaldi A, Jacobs BP, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst Rev. 2007;(4):CD003620.
Fried MW, Navarro VJ, Afdhal N, et al. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. JAMA. 2012;308(3):274–282.
Mengs U, Pohl RT, Mitchell T. Legalon SIL: the antidote of choice in patients with acute hepatotoxicity from amatoxin poisoning. Curr Pharm Biotechnol. 2012;13(10):1964–1970.
Kars M, Yang L, Gregor MF, et al. Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes. 2010;59(8):1899–1905.
Vang S, Longley K, Steer CJ, Low WC. The unexpected uses of urso- and tauroursodeoxycholic acid in the treatment of non-liver diseases. Glob Adv Health Med. 2014;3(3):58–69.